cancer

Study finds that that men who aren’t well educated about their disease have a much more difficult time making treatment decisions. This "decisional conflict" could negatively impact their long-term outcomes.

Approval of Keytruda signals a paradigm shift in the way advanced melanoma is treated. The drug was tested on more than 600 patients in the U.S., Europe and Australia.

Dr. Denis Evseenko’s bold vision of translational science is already blazing new trails in research of regenerative stem cells and their relationship to cancer at the Jonsson Comprehensive Cancer Center and the Broad Center for Stem Cell Research at UCLA.

The researchers' findings could lead to cancer treatments that are more effective with smaller doses and to therapies that could potentially eradicate the HIV virus.

On August 22 at 2 p.m., Mattel Children’s Hospital UCLA will host a St. Baldrick’s Foundation signature head-shaving event to raise funds and awareness for lifesaving childhood cancer research. The goal is to raise $5,000.

Inspired by her memories of her daughter, Paulinda Babbini created a nonprofit to raise money to fund the work of a UCLA scientist who focuses on gynecological cancers.

Men with prostate cancer who were also depressed were more likely to be diagnosed with more aggressive prostate cancer, receive less effective treatments and survive for shorter times.

A UCLA-led study found that a new surgical technique is more effective than other current techniques to remove kidney tumors when the masses are located on the back of the kidney or when a patient has had previous abdominal surgery.

Findings from the three-year study could eventually lead to new personalized treatments for lung cancer, which is responsible for an estimated 29 percent of U.S. cancer deaths.

Two experimental drugs were shown in clinical trials to increase survival times with fewer toxic side effects than standard treatments.

In clinical trials at UCLA, doctors are seeing major treatment successes with an experimental drug called MK-3475 in two types of cancer with historically low survival rates: metastatic melanoma and lung cancer.

UCLA researchers have discovered that the parasite that causes trichomoniasis, a common sexual infection, may enhance prostate cells' progression from normal cells to tumor cells.

Using an MRI-ultrasound fusion biopsy developed at UCLA, researchers found that nearly a third of men in their study had much more aggressive cancers than originally thought.

Our national system for delivering high-quality cancer care is groaning under the weight of an increasing patient population, spiraling costs and an impending shortage of qualified providers. Cancer-care expert Dr. Patricia A. Ganz talks about the sweeping changes that must be made.

Scientists at UCLA's Jonsson Comprehensive Cancer Center have published the first study explaining in detail how viruses reprogram the metabolism of the cells they invade to promote continued viral growth within an organism.

Using an existing drug and a new drug developed at UCLA, the researchers eradicated cancer cells in mice with a deadly type of blood cancer, leaving healthy blood cells alone. The treatment might also have applications for other blood diseases.

Nanomedicine has proven to be promising in fighting cancer, offering the prospect of safer and more effective imaging and drug delivery, and the ability to target tumor cells while sparing patients' healthy tissue.

The UCLA Specialized Program of Research Excellence team is a multidisciplinary group of scientists striving to find a cure for a cancer that will affect roughly one in six men.